Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Walgreens Boots Alliance Inc    

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Active Flu Season Boosts Walgreen's January Sales

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/05/2013 | 07:36pm CEST

Walgreen Co. (>> Walgreen Company) posted its first monthly same-store sales gain in a year in January, aided by an active flu season and firmer prescription orders stemming from the resolution of a contract dispute with a major pharmacy-benefits manager.

The 3.7% increase in same-store sales in January came above the projected 1.5% increase, according to analysts surveyed by Thomson Reuters.

Results last year were hurt by a rate contract dispute with pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that led millions to transfer their prescriptions to rival pharmacies. But since Walgreen and Express Scripts entered a new multiyear agreement that began in September, millions have returned to the fold.

The loss of the Express Scripts customers, as well as higher demand for lower-priced generic drugs, hurt Walgreen's same-store sales throughout 2012. In 2012, January's same-store sales dropped 4.6%.

Walgreen has also successfully courted some customers it had lost in the dispute and hopes to win back more, gains executives expect will be reflected in many of 2013's monthly sales reports. In January, pharmacy sales grew 8.7% and same-store pharmacy sales increased 6.2%, compared with an expected 2.4% jump. Prescriptions filled at comparable stores soared 14%.

Overall, total sales in January grew 6.3% to $6.15 billion from a year ago. Front-end sales were up 1.3%, while same-store front-end sales slid 0.4%, compared with expectations of a 0.5% drop.

Drugstore front-end sales have been helped by a nasty flu season, bolstering traffic and demand for prescriptions and over-the-counter treatments. Walgreen, which provides more flu vaccines in the U.S. than any other retailer, said it has administered 6.9 million flu vaccines so far this season, far above last year's 5.5 million.

But drugstore-retailer results have been stung by increasing demand for generic drugs, which Walgreen said hurt January's pharmacy same-store sales by six percentage points. Strong demand for those drugs products a mixed effect because copycat drugs carry higher margins than branded products but command lower prices, hurting same-store sales.

Last week, Rite Aid Corp. (>> Rite Aid Corporation) reported January same-store sales were up 0.3%, as a very active flu season helped offset the pressure from generics. CVS Caremark Corp. (>> CVS Caremark Corporation), which doesn't report monthly sales data, has already warned same-store sales in the first quarter would be lower. The company's full fourth-quarter results are due on Wednesday.

Walgreen's shares were inactive at $40.01 in premarket trading.

Write to John Kell at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on WALGREENS BOOTS ALLIANCE I
10/20WALGREENS BOOTS ALLIANCE INC : annual earnings release
10/18 WALGREENS BOOTS ALLIANCE : to Establish New Technology Center of Excellence in t..
10/17 WALGREENS : to Establish New Technology Center of Excellence in the Sullivan Cen..
10/17 Amneal, Impax combine to tackle generic drug pricing pressure
10/16 U.S. top court to review antitrust claims against American Express
10/16 U.S. top court to review antitrust claims against American Express
10/09 Pfizer Inc. AmerisourceBergen, Blue Cross Blue Shield Association
10/07 INTERRA RESOURCES : Rite Aid stores to disappear from South Carolina after Walgr..
10/06 Drug chains tumble on reports Amazon eyeing their pie
10/06 Drug chains tumble on reports Amazon eyeing their pie
More news
Financials ($)
Sales 2017 118 B
EBIT 2017 7 166 M
Net income 2017 4 449 M
Debt 2017 10 148 M
Yield 2017 2,23%
P/E ratio 2017 16,19
P/E ratio 2018 14,01
EV / Sales 2017 0,70x
EV / Sales 2018 0,67x
Capitalization 72 831 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 88,8 $
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Stefano Pessina Executive Vice Chairman & Chief Executive Officer
James A. Skinner Executive Chairman
Ornella Barra Co-Chief Operating Officer
Alexander W. Gourlay Co-Chief Operating Officer
George Rollo Fairweather Global Chief Financial Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
WALGREENS BOOTS ALLIANCE INC72 831
CVS HEALTH-5.42%77 757
WALGREENS BOOTS ALLIANCE-18.15%72 831
EXPRESS SCRIPTS HOLDING CO-16.02%34 370
MCKESSON CORPORATION6.77%31 703
CARDINAL HEALTH INC-7.31%21 028